prikaz prve stranice dokumenta Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
  Preuzmi
PDF 168.77 KB
Znanstveni rad - Prikaz slučaja
Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
Medicine, 97 (2018), 51; e13671. https://doi.org/10.1097/MD.0000000000013671
Begovac, Josip; Krznarić, Juraj; Bogdanić, Nikolina; Močibob, Loris; Zekan, Šime

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Begovac, J., Krznarić, J., Bogdanić, N., Močibob, L. i Zekan, Š. (2018). Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir. Medicine, 97. (51). doi: 10.1097/MD.0000000000013671

Begovac, Josip, et al. "Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir." Medicine, vol. 97, br. 51, 2018. https://doi.org/10.1097/MD.0000000000013671

Begovac, Josip, Juraj Krznarić, Nikolina Bogdanić, Loris Močibob i Šime Zekan. "Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir." Medicine 97, br. 51 (2018). https://doi.org/10.1097/MD.0000000000013671

Begovac, J., et al. (2018) 'Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir', Medicine, 97(51). doi: 10.1097/MD.0000000000013671

Begovac J, Krznarić J, Bogdanić N, Močibob L, Zekan Š. Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir. Medicine [Internet]. 12.2018. [pristupljeno 25.12.2024.];97(51). doi: 10.1097/MD.0000000000013671

J. Begovac, J. Krznarić, N. Bogdanić, L. Močibob i Š. Zekan, "Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir", Medicine, vol. 97, br. 51, Prosinac 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:507305. [Citirano: 25.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:507305
Podaci o radu
Naslov (engleski)Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
AutorJosip Begovac
AutorJuraj Krznarić
AutorNikolina Bogdanić
AutorLoris Močibob
AutorŠime Zekan
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
RATIONALE: Data on anti-HCV therapy in patients on dialysis is still evolving. Sofosbuvir is mainly eliminated through the renal route and there is controversy about its use in these patients. ----- PATIENT CONCERNS: We describe a 53-year-old male patient with HCV genotype 3 and human immunodeficiency type 1 (HIV) infection on chronic dialysis. HIV infection was diagnosed in 1987 and since July 2007 the patient was compliant with his antiretroviral therapy (ART) and had an undetectable plasma HIV viral load on all follow-up measurements. The patient was known to have HCV infection since 1997 but has never been treated for chronic hepatitis C. Because of progressive renal impairment dialysis started in 2005. ----- DIAGNOSIS: Before anti-HCV treatment commenced the patient liver transient elastography (FibroScan) indicated F3 fibrosis (stiffness, 11.6 kPa) and his HCV RNA viral load was 320,798 IU/mL (Abbott RealTime HCV assay). ----- INTERVENTION: Fixed dose combination of sofosbuvir/velpatasvir (400 mg/100 mg) for 11 weeks. ----- OUTCOMES: Twelve weeks after treatment cessation HCV RNA was undetectable, hence the patient achieved a sustained virologic response. The drugs were well tolerated and the patient did not report any side effects. ----- LESSONS: Sofosbuvir/velpatasvir may be an option for HCV genotype 3 infection in patients coinfected with HIV on long-term dialysis.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMedicine
Brojčani podacivol. 97, br. 51, e13671
p-ISSN0025-7974
DOIhttps://doi.org/10.1097/MD.0000000000013671
URN:NBNurn:nbn:hr:105:507305
Datum objave publikacije2018-12
URL dokumentahttps://doi.org/10.1097/MD.0000000000013671
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:59:44